FDA OKs Drug for Hemophilia A With Factor VIII Inhibitors
Weekly prophylactic treatment associated with substantial decrease in bleeding episodes (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Internal Medicine, Critical Care, Emergency Medicine, Nursing, Oncology, Pathology, Pharmacy, Institutional, Source Type: news

Emicizumab Prophylaxis Cuts Bleeding in Hemophilia A
Lower bleeding rate with administration once weekly, every two weeks versus no prophylaxis (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Internal Medicine, Oncology, Journal, Source Type: news

Obizur Antihemophilic Factor (recombinant) for the Treatment of Acquired Haemophilia A
Obizur antihemophilic factor (recombinant) is the first recombinant porcine FVIII indicated for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). (Source: Drug Development Technology)
Source: Drug Development Technology - November 10, 2014 Category: Pharmaceuticals Source Type: news

Falling and fall risk factors in adults with haemophilia: an exploratory study - Sammels M, Vandesande J, Vlaeyen E, Peerlinck K, Milisen K.
Falls are a particular risk in persons with haemophilia (PWH) because of damaged joints, high risk of bleeding, possible impact on the musculoskeletal system and functioning and costs associated with treatment for these fall-related injuries. In addition, ... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - November 1, 2014 Category: Global & Universal Tags: Age: Elder Adults Source Type: news

FDA Approves New Treatment for Hemophilia
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 28, 2014 Category: Journals (General) Source Type: news

Rixubis Recommended by EMA Panel for Hemophilia BRixubis Recommended by EMA Panel for Hemophilia B
Rixubis has been recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use for prophylaxis and treatment of bleeding in patients with hemophilia B. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 28, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Exclusive: Baxter's new hemophilia drug has its roots in Bala Cynwyd
A new hemophilia treatment has just been approved by the FDA, and it has its roots in the Philadelphia region. The drug is called Obizur, and much of its development was done by Octagen, a Bala Cynwyd, Pa. biotechnology company. The drug is now owned by Baxter International. Acquired hemophilia A is a rare and potentially life-threatening bleeding disorder that, unlike congenital hemophilia, typically affects older adults. It occurs equally in both males and females. Octagen — a company founded… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 27, 2014 Category: American Health Authors: John George Source Type: news

Baxter's blood disorder drug gets FDA approval
(Reuters) - (This Oct. 24 story has been corrected to remove paragraph saying that Obizur will compete with Biogen Idec Inc's BIIB.O Eloctate. Eloctate is approved to treat congenital hemophilia A, not acquired hemophilia A) (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Revised Spanish Article-Hemophilia
Hemophilia (heem-o-FILL-ee-ah) is a rare bleeding disorder in which the blood doesn't clot normally. (Source: National Heart, Lung, and Blood Institute Health Topics)
Source: National Heart, Lung, and Blood Institute Health Topics - October 27, 2014 Category: Consumer Health News Source Type: news

New Spanish Article-Hemophilia
New Spanish language article on arrhythmia. (Source: National Heart, Lung, and Blood Institute Health Topics)
Source: National Heart, Lung, and Blood Institute Health Topics - October 27, 2014 Category: Consumer Health News Source Type: news

D.C. Week: ACA Grants Announced, Hemophilia Drug OK'd
(MedPage Today) -- An $840 million initiative to hold down costs. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - October 25, 2014 Category: Geriatrics Source Type: news

New Treatment Approved for Rare Form of Hemophilia
The bleeding disorder affects both males and females Source: HealthDay Related MedlinePlus Page: Hemophilia (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 24, 2014 Category: Consumer Health News Source Type: news

FDA approves new treatment for rare form of hemophilia
The U.S. Food and Drug Administration yesterday approved Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A (acquired Factor VIII [FVII] deficiency). (Source: Food and Drug Administration)
Source: Food and Drug Administration - October 24, 2014 Category: American Health Source Type: news

Haemophiliacs seek access to new treatment
Group says 350 Hepatitis C patients urgently need new therapies to stay alive (Source: The Irish Times - Health)
Source: The Irish Times - Health - September 15, 2014 Category: Consumer Health News Source Type: news

Using Plant Cells to Help Treat Hemophilia
Accidents as minor as a slip of the knife while chopping onions can turn dangerous for patients with hemophilia, who lack the necessary proteins in their blood to stem the flow from a wound. (Source: Disabled World)
Source: Disabled World - September 5, 2014 Category: Disability Tags: Medical Source Type: news

“Nothing About Us, Without Us”
National Hemophilia Foundation Encourages Patient Community to Take an Active Part in Strategies, Policies, and Programs Directly Affecting Their Lives at 66th Annual Meeting in Washington, DC(PRWeb September 04, 2014)Read the full story at http://www.prweb.com/releases/2014/9/prweb12142097.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 4, 2014 Category: Pharmaceuticals Source Type: news

Plant-based research prevents complication of hemophilia treatment in mice
A strategy to prevent one of the most serious complications of hemophilia treatment is underway at an American university. The approach, which uses plant cells to teach the immune system to tolerate rather than attack the clotting factor protein, offers hope for preventing one of the most serious complications of hemophilia treatment. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 4, 2014 Category: Science Source Type: news

Researchers turn to plants to help treat hemophilia
(University of Florida) Accidents as minor as a slip of the knife while chopping onions can turn dangerous for patients with hemophilia, who lack the necessary proteins in their blood to stem the flow from a wound. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 4, 2014 Category: Global & Universal Source Type: news

Plant-based research at Penn prevents complication of hemophilia treatment in mice
(University of Pennsylvania) In a new study, researchers from the University of Pennsylvania School of Dental Medicine and the University of Florida College of Medicine teamed up to develop a strategy to prevent one of the most serious complications of hemophilia treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 4, 2014 Category: Global & Universal Source Type: news

Health Canada Approves Eloctate(TM), the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A
Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Regimens of Either Every Three to Five Days or Once-Weekly Infusions MISSISSAUGA, ON,(Healthcare Sales & Marketing Network) - Today Biogen Idec (BIIB) announces that Health Canad... Biopharmaceuticals, RegulatoryBiogen Idec, ELOCTATE, Antihemophilic Factor, hemophilia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 26, 2014 Category: Pharmaceuticals Source Type: news

Baxter reports top-line results from BAX 855 Phase III clinical trial
Baxter International has reported top-line results from its BAX 855 Phase III clinical trial, which is an investigational and extended half-life recombinant factor VIII (rFVIII) treatment for haemophilia A based on ADVATE [Antihemophilic Factor (Reco… (Source: Drug Development Technology)
Source: Drug Development Technology - August 22, 2014 Category: Pharmaceuticals Source Type: news

Long-acting version of Baxter's hemophilia drug succeeds in study
(Reuters) - Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - August 21, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

EMA grants orphan drug designations to Alnylam’s ALN-AT3 for haemophilia treatment
Biopharmaceutical company Alnylam Pharmaceuticals has received orphan drug designations for ALN-AT3 from the European Medicines Agency (EMA) Committee to treat haemophilia A and B. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 8, 2014 Category: Pharmaceuticals Source Type: news

Hemophilia
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 28, 2014 Category: Journals (General) Source Type: news

Pfizer reports positive Phase III results for haemophilia B treatment BeneFIX
Pfizer has reported positive results from its Phase III trial comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe haemophilia B. (Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2014 Category: Pharmaceuticals Source Type: news

Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA (BeneFIX(R)) Once-Weekly Prophylaxis For Hemophilia B
Once-Weekly Prophylaxis Treatment with BeneFIX® Significantly Reduced Annualized Bleeding Rate Compared to On-Demand Treatment NEW YORK--(Healthcare Sales & Marketing Network)--Pfizer Inc. (PFE) today announced the positive results of a Phase 3 stud... BiopharmaceuticalsPfizer, BeneFIX, Factor IX, hemophilia B (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 16, 2014 Category: Pharmaceuticals Source Type: news

Lives: My Mother’s Miracle-Water Cure
When she arrived back home with a large plastic container, I knew there would be trouble. (Source: NYT Health)
Source: NYT Health - July 11, 2014 Category: Consumer Health News Authors: By MICHELLE HERRERA MULLIGAN Tags: Water Alternative and Complementary Medicine Hemophilia Source Type: news

Patient Organization Initiates Practice Guidelines on Hemophilia Care
The National Hemophilia Foundation (NHF) with the guidance of its Medical and Scientific Advisory Council (MASAC), today announced that it is initiating a multi-year project to develop evidence-based...(PRWeb June 26, 2014)Read the full story at http://www.prweb.com/releases/NHF/MASAC/prweb11976000.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 26, 2014 Category: Pharmaceuticals Source Type: news

Hemophilia Treatment Market: Global Analysis, Size, Share, Growth,...
Transparency Market Research published a new report "Hemophilia Treatment Market: Global Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store.Browse the full...(PRWeb June 24, 2014)Read the full story at http://www.prweb.com/releases/2014/06/prweb11966218.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 24, 2014 Category: Pharmaceuticals Source Type: news

Eloctate for Treatment of Haemophilia A
Eloctate is a drug approved for the control and prevention of bleeding episodes in children and adult haemophilia A patients. (Source: Drug Development Technology)
Source: Drug Development Technology - June 24, 2014 Category: Pharmaceuticals Source Type: news

21.06.14: Not intended for UK Media
Bayer HealthCare and Dimension Therapeutics to Develop Novel Gene Therapy for Hemophilia Amehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 24, 2014 Category: Pharmaceuticals Source Type: news

Bayer bets on gene therapy with Dimension deal
FRANKFURT/LONDON (Reuters) - Bayer has struck an alliance with U.S. biotech firm Dimension Therapeutics to develop a gene therapy for the treatment of haemophilia A, marking renewed interest in an approach to tackle the cause of diseases at a cellular level. (Source: Reuters: Health)
Source: Reuters: Health - June 23, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

National Hemophilia Foundation Announces the Launch of the Newly...
Redesigned Website Positions NHF as Global Leader of Information to the Bleeding Disorders Community(PRWeb June 11, 2014)Read the full story at http://www.prweb.com/releases/2014/6/prweb11929875.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 11, 2014 Category: Pharmaceuticals Source Type: news

Hemophilia Treatment Market: Global Industry Analysis, Size, Share,...
Transparency Market Research added a new report "Hemophilia Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store. Browse the...(PRWeb June 10, 2014)Read the full story at http://www.prweb.com/releases/2014/06/prweb11930402.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 11, 2014 Category: Pharmaceuticals Source Type: news

Biogen Snags FDA Approval for Second Hemophilia Drug
The U.S. FDA said on Friday it approved Biogen Idec's long-lasting hemophilia A drug, Eloctate, adding another product to the company's emergent portfolio of non-malignant blood disorder drugs. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 10, 2014 Category: Pharmaceuticals Source Type: news

New Hemophilia Remedy Offers Potential for Fewer Injections
Title: New Hemophilia Remedy Offers Potential for Fewer InjectionsCategory: Health NewsCreated: 6/9/2014 12:35:00 PMLast Editorial Review: 6/10/2014 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - June 10, 2014 Category: Cardiology Source Type: news

FDA Clears First Long-Acting Hemophilia A Drug (Eloctate)FDA Clears First Long-Acting Hemophilia A Drug (Eloctate)
Eloctate requires fewer injections when used to prevent or reduce the frequency of bleeding than currently available products. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 10, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

New Long-Acting Hemophilia A Drug Approved (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and Jaye Elizabeth Hefner, MD The FDA has approved Eloctate, a new prophylactic treatment for children and adults … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 9, 2014 Category: Primary Care Source Type: news

Biogen Idec receives FDA approval for haemophilia A drug
Biogen Idec has received approval from the US Food and Drug Administration (FDA) for its Eloctate to control and prevent bleeding episodes, perioperative management, as well as routine prophylaxis in adults and children with haemophilia A. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 9, 2014 Category: Pharmaceuticals Source Type: news

Hemophilia A Drug Gets FDA Nod
(MedPage Today) -- SILVER SPRING, Md. -- A recombinant fusion drug combining the Factor VIII protein with a peptide to extend its lifetime in circulation has been approved for treating hemophilia A, the FDA said. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 7, 2014 Category: American Health Source Type: news

U.S. FDA approves Biogen's hemophilia A drug Eloctate
WASHINGTON (Reuters) - The U.S. Food and Drug Administration said on Friday it approved Biogen Idec Inc's long-lasting hemophilia A drug, Eloctate, adding another product to the company's nascent portfolio of drugs for non-malignant blood disorders. (Source: Reuters: Health)
Source: Reuters: Health - June 6, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves the first antihemophilic factor, Fc fusion protein for patients with Hemophilia A
The U.S. Food and Drug Administration today approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have Hemophilia A. Eloctate is the first Hemophilia A treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding. (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 6, 2014 Category: American Health Source Type: news

Haemophilia and gene therapy
Attendees at the 19th Congress of the European Hematology Association will hear how patients are benefiting from advances in gene therapy, genome sequencing and new drug development. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 4, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: Haematology European Hematology Association Congress Featured Articles gene therapy Haemophilia Source Type: news

EMA adopts positive opinion on Octapharma’s haemophilia A drug Nuwiq
The European Medicines Agency (EMA) has given a positive opinion towards Octapharma's human cell line recombinant human FVIII, Nuwiq, recommending the granting of marketing authorisation for treatment and prophylaxis of bleeding in paediatric and adu… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 28, 2014 Category: Pharmaceuticals Source Type: news

Biogen to Donate 1 Billion Units of Hemophilia Treatment
Australia-based Biogen Idec announced their intent to donate one billion international units of clotting factor therapy for humanitarian aid programs in the developing world. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 13, 2014 Category: Pharmaceuticals Source Type: news

Bayer's Kogenate FS gets FDA approval for routine prophylaxis in Hemophilia A patients
Bayer HealthCare has received approval from the US Food and Drug Administration (FDA) for a new indication of its Kogenate FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 13, 2014 Category: Pharmaceuticals Source Type: news

Biogen, Sobi pledge hemophilia drug donation in developing world
(Reuters) - Biogen Idec Inc and partner Swedish Orphan Biovitrum AB on Monday said they will donate hemophilia drugs for use in developing nations in quantities large enough to treat tens of thousands of patients over the next decade. (Source: Reuters: Health)
Source: Reuters: Health - May 12, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Akorn Announces $440M VersaPharm Acquisition
Akorn aims to increase presence in the niche dermatology, tuberculosis and hemophilia markets (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 9, 2014 Category: Pharmaceuticals Source Type: news

Haemophilia society marks 25th anniversary of pivotal HIV debate
Howlin recalls his Bill which brought down Haughey government in 1989 (Source: The Irish Times - Health)
Source: The Irish Times - Health - April 29, 2014 Category: Consumer Health News Source Type: news

Kenya: The Pain of Living With Haemophilia
[Capital FM]Nairobi -"The hardest and most painful thing all through has been to tell my son that he cannot play football, yet when he asks why I cannot tell him that the actual reason is that his falling could prove to be fatal," narrates Lucy Kago a mother to Simon Musyoka who at seven years old, has protrusions on his elbow and ankles that at times are the cause of his excruciating pain. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 22, 2014 Category: African Health Source Type: news